Depression is a leading cause of disability worldwide and a major contributor to the burden
of suicide. A major limitation of classical antidepressants is that 2–4 weeks of continuous …

Ketamine exerts rapid and long-lasting antidepressant effects in patients with treatment-
resistant depression. However, its clinical use is limited by its undesirable psychotomimetic …

Glutamatergic transmission is widely implicated in neuropsychiatric disorders, and the
discovery that ketamine elicits rapid-acting antidepressant effects by modulating α-amino-3 …

Major depressive disorder (MDD) is a highly prevalent and disabling disorder. Despite the
many hypotheses proposed to understand the molecular pathophysiology of depression, it is …

L-Glutamic acid is the main excitatory neurotransmitter in the central nervous system (CNS).
Its associated receptors localized on neuronal and non-neuronal cells mediate rapid …

Depression is a major psychiatric disorder affecting more than 120 million people worldwide
every year. Changes in monoaminergic transmitter release are suggested to take part in the …

Psychedelic drugs acting as 5-hydroxyptryptamine 2A receptor (5-HT 2A R) agonists have
shown promise as viable treatments of psychiatric disorders, including obsessive …

Bisphenol-A (BPA) is a lipophilic, organic, synthetic compound that has been used as an
additive in polycarbonate plastics manufacturing since 1957. Studies have shown that BPA …

Although deep brain stimulation (DBS) has been used with success in treatment-resistant
depression, little is known about its mechanism of action. We examined the antidepressant …

AMPA receptors are tetrameric ionic glutamate receptors, which mediate 90% fast excitatory
synaptic transmission induced by excitatory glutamate in the mammalian central nervous …